Folic acid mediated cisplatin magnetic nanodrug targeting in the treatment of oral squamous cell carcinoma

Cisplatin, a non-specific cell cycle antineoplastic drug, has therapeutic effects on a variety of malignant tumors. However, cisplatin has some drawbacks, such as poor targeting, which can lead to damage in normal tissue adjacent to a cancer, causing serious side effects in patients. In this study, we designed and developed a folic acid (FA)-mediated cisplatin magnetic nanodrug, FA-CDDP-MNPs, and investigated its efficacy in the treatment of oral squamous cell carcinoma (OSCC). In vitro and in vivo experiments showed that FA-CDDP-MNPs had a greater inhibitory effect on OSCC than CDDP alone. Due to the introduction of FA, the targeting of FA-CDDP-MNPs was improved, and its cytotoxicity reduced. The successful design and development of FA-CDDP-MNPs provides a basis for novel drug development and design in the future.